Abbott (ABT)
Makes glucose monitors, cardiovascular devices, diagnostic tests, nutrition products, and branded generic medicines.
$104.00
After hours+0.28 (+0.27%)
At close$103.72(+0.72%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10,143 | 10,241 | 9,964 | 10,377 | 10,635 | 10,974 | 10,358 | 11,142 | 11,369 | 11,459 | 11,164 | 12,593 |
| Cost of revenue | 5,109 | 4,983 | 4,942 | 5,072 | 5,209 | 5,376 | 4,914 | 4,854 | 5,031 | 4,922 | 4,881 | 5,289 |
| Gross profit | 5,034 | 5,258 | 5,022 | 5,305 | 5,426 | 5,598 | 5,444 | 6,288 | 6,338 | 6,537 | 6,283 | 7,304 |
| 3,356 | 3,394 | 3,637 | 3,619 | 3,608 | 3,608 | 3,756 | 4,236 | 4,308 | 4,286 | 4,441 | 5,522 | |
| Research & development | 661 | 690 | 683 | 697 | 713 | 728 | 703 | 732 | 785 | 735 | 756 | 882 |
| 2,695 | 2,704 | 2,954 | 2,922 | 2,895 | 2,880 | 3,053 | 3,093 | 3,103 | 3,129 | 3,263 | 3,982 | |
| General & administrative | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3,129 | 0 | 0 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 411 | 420 | 422 | 422 | 658 |
| Operating income | 1,678 | 1,864 | 1,385 | 1,686 | 1,818 | 1,990 | 1,688 | 2,052 | 2,057 | 2,251 | 1,842 | 1,782 |
| −7 | −69 | 51 | −79 | 122 | 40 | 90 | 98 | 123 | 107 | −393 | −258 | |
| Interest income | 97 | 89 | 80 | 82 | 91 | 91 | 82 | 71 | 77 | 78 | 106 | 0 |
| Interest expense | 148 | 235 | 117 | 168 | 166 | 152 | 134 | 121 | 44 | 120 | 174 | 299 |
| Other non-operating income | −141 | −166 | −168 | −89 | −288 | −192 | −224 | −219 | −244 | −149 | 325 | 0 |
| Income before tax | 1,671 | 1,795 | 1,436 | 1,607 | 1,940 | 2,030 | 1,778 | 2,150 | 2,180 | 2,358 | 1,449 | 1,524 |
| Income tax expense | 235 | 201 | 211 | 305 | 294 | −7,199 | 453 | 371 | 536 | 582 | 372 | 596 |
| Net income from continuing operations | 1,436 | 1,594 | 1,225 | 1,302 | 1,646 | 9,229 | 1,325 | 1,779 | 1,644 | 1,776 | 1,077 | 928 |
| Net income | 1,436 | 1,594 | 1,225 | 1,302 | 1,646 | 9,229 | 1,325 | 1,779 | 1,644 | 1,776 | 1,077 | 928 |
| EPS, basic | $0.83 | $0.92 | $0.71 | $0.75 | $0.95 | $5.33 | $0.76 | $1.02 | $0.94 | $1.02 | $0.62 | $0.53 |
| EPS, diluted | $0.82 | $0.91 | $0.70 | $0.74 | $0.94 | $5.27 | $0.76 | $1.01 | $0.94 | $1.02 | $0.62 | $0.53 |
| Weighted average shares, basic | 1,739 | 1,734 | 1,734 | 1,734 | 1,734 | 1,732 | 1,747 | 1,740 | 1,749 | 1,747 | 1,747 | 1,743 |
| Weighted average shares, diluted | 1,748 | 1,748 | 1,750 | 1,751 | 1,748 | 1,746 | 1,747 | 1,751 | 1,749 | 1,747 | 1,747 | 1,743 |
| EBITDA | 2,643 | 2,843 | 2,358 | 2,580 | 2,907 | 2,989 | 2,668 | 3,048 | 3,092 | 2,822 | 2,247 | 1,782 |
| Depreciation & amortization | 824 | 813 | 805 | 805 | 801 | 807 | 756 | 777 | 791 | 422 | 730 | 0 |
| EBIT | 1,819 | 2,030 | 1,553 | 1,775 | 2,106 | 2,182 | 1,912 | 2,271 | 2,301 | 2,400 | 1,517 | 1,782 |